Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment Juul M.P.A.

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis Juan Escalas, PhD, MD, Nicole Knöpfel, MD, Ana Martin-Santiago,

A randomized controlled pilot study of strategies to increase adherence in teenagers with acne vulgaris Brad A. Yentzer, MD, Amy L. Gosnell, MD, Adele.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Baldness reversed by chemotherapy

Efficacy of simvastatin in plaque psoriasis: A pilot study

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Remission and time of resolution of nail psoriasis during infliximab therapy Luca Bianchi, MD, Antonio Bergamin, MD, Catia de Felice, MD, Elisabetta Capriotti,

Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis Federica Ricceri, MD, Leonardo.

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment Juul M.P.A.

Brad A. Yentzer, MD, Ali Alikhan, BS, Hoa Teuschler, MS, Lisa L

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Assessing adherence with phototherapy protocols

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Pilot study of a skin cancer education curriculum for medical students

Pain and nonmelanoma skin cancer in transplant patients

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Plasma β-endorphin levels in frequent and infrequent tanners before and after ultraviolet and non-ultraviolet stimuli Mandeep Kaur, MD, Anthony Liguori,

Severe hypoglycemia after initiation of anti–tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2.

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Partik Singh, BA, Jonathan I. Silverberg, MD, MPH, PhD

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Infectious rash after riding elephants

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Recurrent erythema multiforme: Clinical characteristics, etiologic associations, and treatment in a series of 48 patients at Mayo Clinic, 2000 to 2007

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis Alexander Nast, Anja Jacobs,

Cost-Effectiveness of Biologic Agents in the Treatment of Moderate-to-Severe Psoriasis: A Brazilian Public Health Service Perspective Bruno Salgado Riveros,

Medicaid acceptance among pediatric dermatologists

Adherence with topical treatment is poor compared with adherence with oral agents: Implications for effective clinical use of topical agents Jennifer.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Guidelines of care for the management of psoriasis and psoriatic arthritis Alan Menter, MD, Neil J. Korman, MD, PhD, Craig A. Elmets, MD, Steven R. Feldman,

Jennifer L. Hundley, MD, Christie L

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Etanercept therapy in two patients with psoriasis and concomitant hepatitis C Clara De Simone, MD, Andrea Paradisi, MD, Rodolfo Capizzi, MD, Angelo Carbone,

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Presentation transcript:

Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period Andrew A. Nelson, MD, Daniel J. Pearce, MD, Alan B. Fleischer, MD, Rajesh Balkrishnan, PhD, Steven R. Feldman, MD, PhD Journal of the American Academy of Dermatology Volume 58, Issue 1, Pages 125-135 (January 2008) DOI: 10.1016/j.jaad.2007.09.018 Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Cost-effectiveness in 2006 US dollars per patient achieving the DLQI MID, assessed over a 12-week treatment course. The slope from the graph origin to each point represents its cost-effectiveness compared with placebo; agents with similar slopes therefore have similar cost-effectiveness ratios. A smaller (lower) slope indicates a more cost-effective medication. Similarly, the slope between any two points in the graph represents the incremental cost-effectiveness ratio between those two medications. A vertical slope or negative slope of the line between medications indicates that the medication is less cost-effective. Agents with similar cost-effectiveness ratios (similar slopes), as determined by overlap in analysis of extreme scenarios at a level of variance of 5%, are shown in the same font in the figure (bold, italics, underlined, or regular). ALF, Alefacept 15 mg IM once weekly; ETN 25/wk, etanercept 25 mg SQ once weekly; ETN 25 2x/wk, etanercept 25 mg SQ twice weekly; ETN 50 2x/wk, etanercept 50 mg SQ twice weekly; ADA eow, adalimumab 40 mg SQ every other week; ADA qweek, adalimumab 40 mg SQ every week; INF 3mg/kg, infliximab 3 mg/kg IV for 3 infusions; INF 5mg/kg, infliximab 5 mg/kg IV for 3 infusions. Journal of the American Academy of Dermatology 2008 58, 125-135DOI: (10.1016/j.jaad.2007.09.018) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Cost-effectiveness in 2006 US dollars per patient achieving PASI-75 improvement, assessed over a 12-week treatment course. Similar to Fig 1, the slope of each line from the origin represents its cost-effectiveness compared to placebo. Also, the slope from any two points represents the incremental cost-effectiveness between the two agents. Agents with similar cost-effectiveness ratios (similar slopes), as determined by overlap in analysis of extreme scenarios at a level of variance of 5%, are shown in the same font in the figure (bold, italics, or regular). See Fig 1 for abbreviations. Journal of the American Academy of Dermatology 2008 58, 125-135DOI: (10.1016/j.jaad.2007.09.018) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions